Baird served as joint book-running manager on this offering.
AboutCerus Corporation (“Cerus” or the “Company”) (NASDAQ:CERS) recently completed a follow-on offering of 14,636,363 shares of common stock at a price of $5.50 per share, generating gross proceeds of approximately $80.5 million. The Company intends to use the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.
Cerus is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, the INTERCEPT platelet and plasma systems have received FDA approval. The INTERCEPT red blood cell system is in clinical development. Cerus is headquartered in Concord, California.
For additional information about this transaction, please contact:
- January 2015
- Cerus Corporation
- Target Location
- North America